Connect to share and comment
BRUSSELS (Reuters) - Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favor of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis.
While the vote was not binding on a final recommendation, it would play a part in the decision to clear the drug for this application in the United States, UCB said.
Axial spondyloarthritis is an inflammatory disease mostly affecting the spine and the pelvis.
(Reporting by Robert-Jan Bartunek; Editing by Matt Driskill)